OROPHARYNX SQUAMOUS CELL CARCINOMA
Clinical trials for OROPHARYNX SQUAMOUS CELL CARCINOMA explained in plain language.
Never miss a new study
Get alerted when new OROPHARYNX SQUAMOUS CELL CARCINOMA trials appear
Sign up with your email to follow new studies for OROPHARYNX SQUAMOUS CELL CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New Two-Drug attack on tough head & neck cancers
Disease control Recruiting nowThis study is testing whether a combination of two drugs, sacituzumab govitecan and cetuximab, can help control advanced head and neck cancer that has come back or spread after initial treatment. It will involve about 40 adults whose cancer has progressed despite standard therapy…
Matched conditions: OROPHARYNX SQUAMOUS CELL CARCINOMA
Phase: PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Mar 30, 2026 14:29 UTC
-
Blood test could transform Follow-Up care for throat cancer survivors
Disease control Recruiting nowThis study is testing a new strategy for monitoring people after treatment for HPV-positive throat cancer. It uses a simple blood test that looks for traces of HPV DNA to check if the cancer might be coming back. The goal is to see if this test can help doctors schedule fewer rou…
Matched conditions: OROPHARYNX SQUAMOUS CELL CARCINOMA
Phase: PHASE2 • Sponsor: UNICANCER • Aim: Disease control
Last updated Mar 25, 2026 14:09 UTC
-
Blood test could spare throat cancer patients harsh radiation
Disease control Recruiting nowThis study is testing a new approach for people with HPV-linked throat cancer who have surgery. Researchers want to see if a simple blood test can identify patients who are very unlikely to need follow-up radiation. If the blood test after surgery shows no signs of cancer, patien…
Matched conditions: OROPHARYNX SQUAMOUS CELL CARCINOMA
Phase: PHASE2 • Sponsor: University of Maryland, Baltimore • Aim: Disease control
Last updated Mar 25, 2026 14:08 UTC
-
New weekly combo aims to control aggressive Head/Neck cancer
Disease control Recruiting nowThis study is testing a weekly combination of chemotherapy and immunotherapy for people with advanced head and neck cancer that has spread and who cannot take a standard chemotherapy drug called 5-FU. The goal is to see if this weekly schedule helps shrink tumors and control the …
Matched conditions: OROPHARYNX SQUAMOUS CELL CARCINOMA
Phase: PHASE2 • Sponsor: Wake Forest University Health Sciences • Aim: Disease control
Last updated Mar 23, 2026 15:17 UTC